Key statistics
As of last trade, Rezolute Inc (RZLT:NAQ) traded at 3.44, 221.50% above the 52 week low of 1.07 set on Dec 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 3.36 |
|---|---|
| High | 3.52 |
| Low | 3.27 |
| Bid | 3.43 |
| Offer | 3.44 |
| Previous close | 3.37 |
| Average volume | 2.77m |
|---|---|
| Shares outstanding | 92.73m |
| Free float | 82.97m |
| P/E (TTM) | -- |
| Market cap | 312.49m USD |
| EPS (TTM) | -0.9291 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 17:01 GMT.
More ▼
- Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
- Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
- Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
- Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
- Rezolute to Host Virtual Investor Event on Ersodetug Development Program
- Rezolute to Participate in Upcoming Investor Conferences
- Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
- Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
More ▼
